Related Experiment Video
Updated: Feb 20, 2026

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices
Published on: June 13, 2025
Recent advances in the management of peptic ulcer bleeding
1Department of Gastroenterology, Norfolk and Norwich University Hospital, Norwich, UK.
Insights
Peptic ulcer bleeding management has advanced with restrictive transfusion strategies and improved risk scoring systems like Glasgow-Blatchford. New research explores pre-endoscopy erythromycin and novel endoscopic techniques for better patient outcomes.
Area of Science:
- Gastroenterology
- Internal Medicine
- Emergency Medicine
Background:
- Acute upper gastrointestinal hemorrhage from peptic ulcers causes significant morbidity, mortality, and healthcare costs.
- Despite published guidelines, management of peptic ulcer bleeding continues to evolve with ongoing research and controversies.
Purpose of the Study:
- To review recent advances and controversies in the management of acute upper gastrointestinal hemorrhage due to peptic ulcer bleeding.
- To highlight new evidence on transfusion strategies, risk stratification scores, endoscopic interventions, and specific ulcer types.
Main Methods:
- Review of recent literature and clinical studies on peptic ulcer bleeding management.
- Analysis of evidence supporting new transfusion strategies, risk scores (Glasgow-Blatchford, AIMS65), pre-endoscopic therapies, and endoscopic techniques.
- Evaluation of outcomes for non-Helicobacter pylori, non-NSAID ulcers.
Main Results:
- A restrictive transfusion strategy (Hb 70-90 g/l) is supported by evidence.
- The Glasgow-Blatchford score is optimal for predicting intervention needs and identifying low-risk patients.
- Pre-endoscopy erythromycin and high-dose oral proton pump inhibitors (PPIs) post-infusion show benefits.
- Haemostatic powders, over-the-scope clips, and Doppler probes offer advanced endoscopic options.
- Non-H. pylori, non-NSAID ulcers present a growing challenge with poor prognosis.
Conclusions:
- Recent advances improve the management of peptic ulcer bleeding, focusing on restrictive transfusion, accurate risk stratification, and enhanced endoscopic therapies.
- Further research is needed to determine optimal management for non-H. pylori, non-NSAID bleeding ulcers, which are associated with higher rebleeding rates and poorer outcomes.
Abstract:
Acute upper gastrointestinal haemorrhage due to peptic ulcer bleeding remains an important cause of emergency presentation and hospital admission. Despite advances in many aspects of management, peptic ulcer bleeding is still associated with significant morbidity, mortality, and healthcare costs. Comprehensive international guidelines have been published, but advances as well as controversies continue to evolve. Important recent advances include the evidence supporting a more restrictive transfusion strategy aiming for a target haemoglobin of 70-90 g/l. Comparative studies have confirmed that the Glasgow-Blatchford score remains the most useful score for predicting the need for intervention as well as for identifying the lowest-risk patients suitable for outpatient management. New scores, including the AIMS65 and Progetto Nazionale Emorragia Digestiva score, may be more accurate in predicting mortality. Pre-endoscopy erythromycin appears to improve outcomes and is probably underused. High-dose oral proton pump inhibition (PPI) for 11 days after PPI infusion is advantageous in those with a Rockall score of 6 or more. Oral is as effective as parenteral iron at restoring haemoglobin levels after a peptic ulcer bleed and both are superior to placebo in this respect. Within endoscopic techniques, haemostatic powders and over-the-scope clips can be used when other methods have failed. A disposable Doppler probe appears to provide more accurate determination of both rebleeding risk and the success of endoscopic therapy than purely visual guidance. Non- Helicobacter pylori, non-aspirin/non-steroidal anti-inflammatory drug ulcers contribute an increasing percentage of bleeding peptic ulcers and are associated with a poor prognosis and high rebleeding rate. The optimal management of these ulcers remains to be determined.
Related Concept Videos
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...

